Quantum Leap Energy and Necsa Forge HALEU Joint Venture in South Africa

A Strategic Partnership for HALEU Production

In a major development for the global HALEU supply chain, US-based Quantum Leap Energy (QLE), a subsidiary of ASP Isotopes, and the South African state-owned company Necsa have signed a binding Heads of Agreement. Announced in mid-October 2026, this framework agreement establishes a joint venture to develop a commercial-scale HALEU production site at the Pelindaba facility near Pretoria, South Africa.

Joint Venture Structure and Responsibilities

The newly formed joint venture features a clear division of equity and operational responsibilities. Quantum Leap Energy will hold approximately 80% equity in the project, taking the lead on operations and capital arrangements. Conversely, Necsa will retain a 20% stake while providing crucial site access, existing nuclear infrastructure, and comprehensive regulatory support. This partnership leverages QLE's financial and operational capabilities alongside Necsa's deep expertise in nuclear safeguards and site management.

The proposed commercial scale HALEU production facility at Pelindaba is supported by offtake agreements with advanced reactor developer TerraPower, securing an identified market for the facility's expected HALEU output.

Regulatory Progress and Project Milestones

The Pelindaba HALEU project is already showing tangible progress. In July 2026, Quantum Leap Energy secured approval from South Africa’s Ministry of Electricity and Energy to acquire, possess, use, and transport source material and nuclear equipment for enrichment activities at the site. Furthermore, a test bench facility has already been constructed, and infrastructure refurbishment is actively underway.

However, stakeholders note that the project is still in its early development phase and does not yet represent active commercial production. HALEU, defined as uranium enriched to more than 5% and less than 20% U-235, is specifically designed for advanced generation nuclear reactors. The facility will require further work, testing, and comprehensive national regulatory authorizations for safety, security, and non-proliferation before full-scale operations can commence. Total costs, job creation metrics, and a firm commercial production timeline are yet to be established.

This article was assisted by AI analysis. Please refer to the original source for official information.